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Scedosporium apiospermum and S. proliﬁ  cans are 
fungi of increasing clinical importance, particularly in per-
sons with underlying diseases. We reviewed the records 
of 59 patients in Australia from whom Scedosporium spp. 
were isolated from June 30, 1997, through December 31, 
2003.  S. apiospermum was isolated predominantly from 
the respiratory tracts of 28 of 31 patients with underlying 
lung diseases and resulted in 2 infections and 1 death. The 
annual number of S. apiospermum isolates remained con-
stant. S. proliﬁ  cans was isolated from 28 patients only after 
November 1999. Eight patients with acute myeloid leukemia 
or hematopoietic stem cell transplants had invasive infec-
tion; 4 had fungemia and 6 died from infection. S. proliﬁ  cans 
caused locally invasive infection in 2 immunocompetent pa-
tients and was found in the respiratory tract of 18 patients 
with underlying respiratory disease but did not cause funge-
mia or deaths in these patients. Scedosporium spp. showed 
distinct clinical and epidemiologic features.
S
cedosporium apiospermum and S. proliﬁ  cans are sap-
rophytic molds with a worldwide distribution. S. apio-
spermum, the anamorph of Pseudallescheria boydii, was 
described more than a century ago as a cause of Madura 
foot and subsequently mycetoma and otitis externa. Re-
cently, it has been isolated from patients with chronic 
lung disease, particularly cystic ﬁ  brosis (1,2), where the 
spectrum of infection ranges from colonization to dis-
seminated infection. S. proliﬁ  cans was ﬁ  rst described as a 
human pathogen in 1984 (3). Scedosporium spp. cause a 
broad spectrum of diseases, including soft tissue infections 
(4–6), septic arthritis (7), osteomyelitis (8,9), ophthalmic 
infections (10–12), sinusitis (13), pneumonia (14,15), men-
ingitis and brain abscesses (16,17), endocarditis (18), and 
disseminated infection (8,18–21). Patients at risk include 
those immunocompromised because of advanced HIV in-
fection (6,18,20), immunosuppressive therapy and neutro-
penia (6,18–21), or intravenous drug use (6,20).
In the ﬁ  nal months of 1999 during construction work, 
an increased number of Scedosporium spp. isolates and S. 
proliﬁ  cans were noted at Alfred Hospital, a university hos-
pital in Prahran, Victoria, Australia, that provides statewide 
trauma, burn, cystic ﬁ   brosis, heart and lung transplant, 
and HIV services. The records of all patients from whom 
Scedosprium spp. were isolated from June 30, 1997, 
through December 31, 2003, were reviewed to describe 
the epidemiology, clinical features, and outcomes of these   
infections.
Methods
Data Collection
Records of all patients with Scedosporium spp. cul-
tured between June 30, 1997, and December 31, 2003, 
were reviewed retrospectively, and demographics, primary 
illness, antifungal therapy, and presence of other patho-
gens, and outcomes were recorded. Immunocompromised 
patients were deﬁ  ned as those with impairment of either or 
both natural and speciﬁ  c immunity to infection (22). Those 
with localized impaired host defenses caused by underly-
ing diseases such as cystic ﬁ  brosis were classiﬁ  ed as im-
munocompetent. Invasive infection was deﬁ  ned as a tissue 
biopsy specimen with hyphae plus culture of the organism 
(23). Disseminated infection was deﬁ  ned as positive blood 
cultures or infection at >2 noncontiguous sites within 7 
days. Neutropenia was deﬁ  ned as an absolute neutrophil 
count <0.5 cells/mm3. Descriptive statistics and odds ratios 
were calculated by using STATA release 8.0 (Stata Corpo-
ration, College Station, TX, USA.)
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Laboratory Methods and Epidemiology
Scedosporium spp. were identiﬁ  ed after culture onto 
horse blood agar and Sabaroud dextrose agar (SDA) and 
incubation at 30°C and 37°C. Colonies were rapid-grow-
ing, gray-white, and downy, with a gray-black reverse side. 
Species were differentiated by microscopic morphology 
(24). Susceptibility testing was performed according to 
Clinical and Laboratory Standards Institute methods (25) 
and synergy studies (2-dimensional 2-agent microdilution 
checkerboard method) (26). Synergy was a summation of 
the fractional inhibitory concentration <0.500.
For comparison of temporal patterns of mold isolates, 
the number of persons with Scedosporium spp. during the 
3 years subsequent to this review (2004–2006) and Asper-
gillus spp. for 1999–2005 were extracted from laboratory 
databases. Rates of detection were expressed as per 1,000 
separations and per 100,000 inpatient-patient days.
Environmental Sampling
From March 2001 through July 2002, environmental 
samples were collected from hospital public access areas 
within and adjacent to the construction site on 7 separate 
occasions. Additional sampling was conducted in ward 
corridors, nursing stations, patient rooms, and the patient 
car park. Air sampling was conducted with a portable high-
volume air sampler (MAS 100; Merck, Darmstadt, Germa-
ny). The volume of air sampled at each site was 1,000 L/10 
min (1 m3). Settle plates were placed in ward corridors and 
patient rooms for 60 min of exposure. Dust was collected 
from horizontal surfaces with sterile swabs moistened with 
sterile saline. Dust and soil specimens were directly placed 
on standard SDA and selective SDA containing amphoteri-
cin B and incubated at 27°C.
Results 
From June 1997 through December 2003, a total of 59 
isolates of Scedosporium spp. were cultured from 56 pa-
tients. S. apiospermum was isolated from 31 patients, and 
S. proliﬁ  cans was isolated from 28 patients. Both species 
were isolated from 3 patients at separate times (12 days, 13 
months, and 27 months apart, respectively). Demographic 
information, coinfections, and outcomes of the patients are 
shown according to the species isolated (Table 1). During 
the period of this review, an average of 28 allogeneic stem 
cell, 35 lung, 27 heart, and 15 renal transplants were per-
formed each year.
S. apiospermum
S. apiospermum was isolated from 32 specimens col-
lected from 31 patients. Twenty-nine isolates were from the 
respiratory tract; sputum (n = 22), bronchoalveolar lavage 
(BAL) (n = 5), sinus (n = 1), and lung tissue (n = 1). The 
remaining 3 isolates were from brain tissue, a central ve-
nous catheter tip, and an ear swab, respectively. No blood 
cultures were positive for S. apiospermum. S. apiospermum 
was isolated concurrently with Aspergillus spp. from the 
respiratory tracts of 9 (29%) of the 31 patients.
Twenty-one (68%) of the 31 patients were immuno-
compromised. Thirteen had undergone solid organ trans-
plantation (11 had lung transplants and 2 had heart trans-
plants), 4 had malignancies (3 had metastatic cancer and 1 
had chronic lymphocytic leukemia), 3 had advanced HIV 
infection, and 1 was receiving immunosuppressive therapy 
for rheumatoid arthritis. All 10 immunocompetent patients 
had chronic respiratory tract disease; cystic ﬁ  brosis (n = 5), 
bronchiectasis (n = 4) and chronic mastoiditis (n = 1).
Three patients were lost to follow-up after isolation of 
S. apiospermum. The remaining 28 patients were followed 
up for a total of 981 months. The mean duration of follow-
up was 35 months (median 16 months, range 1–96 months). 
Two (6%) of the 31 patients had invasive infections. The 
ﬁ  rst patient was a woman who received a lung transplant 5 
years earlier and was previously colonized with Aspergil-
lus spp. but not S. apiospermum. She had pulmonary and 
cerebral lesions and was treated with amphotericin B de-
oxycholate and itraconazole for presumed aspergillosis. S. 
apiospermum was isolated from postmortem lung and brain 
tissue. The second patient was a man who had advanced 
HIV infection with fungal sinusitis on biopsy. He was treat-
ed with voriconazole and surgery but died 3 months later 
from infection with cytomegalovirus. There were 6 deaths 
within 1 month of isolation of S. apiospermum. All deaths 
occurred in immunocompromised patients but only 1 was 
directly attributable to S. apiospermum. The other deaths 
resulted from the underlying condition.
Four patients with chronic lung disease were receiv-
ing itraconazole for treatment of Aspergillus spp. infection 
at the time S. apiospermum was isolated. Three of these 
patients died of respiratory failure 7, 9, and 16 months, re-
spectively, after isolation of S. apiospermum, and 1 was 
alive when last seen 96 months after fungal isolation. 
Seven patients received antifungal therapy after isolation 
of S. apiospermum from respiratory tract samples (4 re-
ceived voriconazole and 3 received itraconazole). These 7 
patients had HIV infection and sinusitis (n = 2), had un-
dergone lung transplantation (n = 3) or had bronchiectasis 
or cystic ﬁ  brosis (n = 2). Both patients with HIV infection 
had sinusitis and died within 7 months of complications of 
HIV. Of the other 5 patients, 4 who received azole therapy 
remained well without invasive infection at 32, 41, 48, and 
88 months, respectively, of follow-up. The remaining treat-
ed patient died 15 months later; death was not attributed to 
fungal infection. The median duration of follow-up of those 
treated with azoles at the time of fungal isolation or sub-
sequent to isolation was 16 months (range 3–96 months); 
S. apiospermum was not subsequently detected in these RESEARCH
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patients. The median duration of follow-up for patients re-
ceiving no treatment after fungal isolation was 19 months 
(range 1–84 months); S. apiospermum was isolated from 
4 of these patients 1, 18, 30, and 36 months, respectively, 
after initial fungal isolation.
S. proliﬁ  cans
S. proliﬁ  cans was isolated from 46 specimens obtained 
from 28 patients. Fourteen (50%) of the 28 patients were 
immunocompetent. Most (12/14, [86%]) specimens from 
immunocompetent patients were from the respiratory tract; 
cystic ﬁ  brosis (n = 6), chronic airway disease (n = 3), na-
sal discharge and sinus aspirates with chronic sinusitis (n = 
3). Patients with cystic ﬁ  brosis or airway disease were not 
considered to have invasive disease and none received an-
tifungal therapy. All 3 patients with chronic sinusitis were 
treated with surgery, and 2 received itraconazole. One iso-
late was from knee cartilage of a patient with hemophilia, 
osteoarthritis, and a knee replacement; the patient under-
went surgery and received itraconazole. S. proliﬁ  cans was 
also isolated from a skin-biopsy specimen from a patient 
with multiple-trauma and cellulitis who was treated only 
with surgery. There were no cases of disseminated infec-
tion or deaths resulting from S. proliﬁ  cans in these immu-
nocompetent patients.
S. proliﬁ  cans was isolated from 14 immunocompro-
mised patients. Immunodeﬁ   ciency was caused by lung 
transplantation (n = 6), hematopoietic stem cell transplan-
tation (HSCT) (n = 6), acute myeloid leukemia (AML), and 
myelodysplastic syndrome (MDS). S. proliﬁ  cans was iso-
lated from BAL of 6 lung transplant recipients. One patient 
was receiving itraconazole for Aspergillus spp. infection, 3 
were receiving voriconazole, and 2 were receiving itracon-
azole and voriconazole with terbinaﬁ  ne. Invasive disease 
did not develop in any of the 4 lung transplant recipients 
who received antifungal treatment and none died. Two lung 
transplant recipients did not receive antifungal treatment. 
One of these patients was lost to follow-up and 1 survived 
>25 months without developing invasive infection, al-
though S. proliﬁ  cans was isolated again 1 year later.
Table 1. Characteristics and outcomes of patients infected with Scedosporium spp., Australia, 1997–2003 
Characteristic S. apiospermum S. prolificans
No. patients  31 28
Patient demographics 
Mean age (range), y  40 42
Sex (M:F)  19:12 16:12
Immunocompromised (%)  21 (68)  14 (50) 
Stem cell transplant  0 6
Hematologic malignancy  0 2
Lung and/or heart transplant  13 6
HIV infection, cancer, immunosuppression  8 0
Immunocompetent (%)  10 (32)  14 (50) 
Cystic fibrosis  5 6
Airways disease*  4 3
Sinusitis 13
Other condition†  0 2
Specimen type 
Respiratory tract (%)  27 (68)  20 (71) 
Tissue 36
Blood 04
Other‡  21
Additional microorganisms identified (%)  16 (42)  14 (50) 
Molds§ 91 0
Bacteria¶  98
Outcome at 1 mo 
Invasive infection (%)#  2 (6)  10 (36) 
Died at 1 mo (%)**  6 (19)  5 (18) 
Died of scedosporiosis (%)†† 1 (3)  5 (18) 
Attributable mortality rate of invasive disease (%)‡‡  1/2 (50)  5/10 (50) 
*Bronchiectasis, asthma, and chronic obstructive pulmonary disease. 
†Osteoarthritis and trauma. 
‡Ear swab, central catheter tip, and synovial fluid. 
§Aspergillus spp, Rhizopus orrhyzae, and Paecilomyces sp. 
¶Bacteria not found in normal flora included Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Staphylococcus aureus, Nocardia sp., and 
Mycobacterium avium complex. 
#Odds ratio (OR) 6.64, 95% confidence interval (CI) 1.62–27.12, p = 0.001. 
**OR 1.11, 95% CI 0.40–3.04, p = 0.84. 
††OR 5.53, 95% CI 0.68–44.54, p = 0.06. 
‡‡OR 1.0, 95% CI 0.21–4.56, p = 1.0. Infection with Scedosporium spp., Australia
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S. proliﬁ  cans was isolated from August 2000 through 
September 2002 from 6 patients undergoing allogeneic 
HSCT and from 2 patients with hematologic malignancy. 
Four of the 6 HSCT recipients had positive blood cultures, 
and 4 recipients had skin lesions (multiple, nodular). Find-
ings for 8 patients in whom invasive disease developed are 
summarized in Table 2. 
Patients 1, 2, and 6 had HSCT complicated by chronic 
extensive refractory graft versus host disease (GVHD). All 
3 died of invasive infection despite treatment with itracon-
azole or voriconazole and terbinaﬁ  ne; 2 had positive blood 
cultures. Infections developed in patients 3, 4, and 5 during 
neutropenia after HSCT. Two of them had positive blood 
cultures, and both died. Patient 4 received no antifungal 
treatment, and patient 5 died despite replacement of pro-
phylactic itraconazole with empiric amphotericin B. Patient 
3, described elsewhere (8), survived after treatment with 
voriconazole, terbinaﬁ  ne, surgery, and neutrophil recovery. 
Patient 7 had MDS and preceding idiopathic CD4-cell lym-
phocytopenia. S. proliﬁ  cans was isolated from sputum, but 
not BAL, and this patient was not treated. One month later, 
S. proliﬁ  cans sinusitis was diagnosed. Despite surgery and 
treatment with itraconazole, followed by voriconazole and 
terbinaﬁ  ne, the patient died. Patient 8, a woman, was neu-
tropenic after remission-induction chemotherapy for AML. 
A swab from a Hickman catheter exit site was positive for 
S. proliﬁ  cans. Subsequently, chest wall cellulitis, deep soft 
tissue infection, and multiple skin nodules developed. She 
was treated with surgery, voriconazole, and terbinaﬁ  ne. 
Her neutropenia resolved and she recovered.
After isolation of S. proliﬁ  cans, 5 of 28 patients were 
lost to follow-up. The remaining 23 were followed up for 
a total of 517 months. Mean length of follow-up was 22.5 
months (median 9 months, range 1–68 months). Invasive 
infection occurred in 10 (36%) of 28 infected with S. proliﬁ  -
cans compared with 2 (6%) of 31 infected with S. apiosper-
mum. Deaths caused by scedosporiosis occurred in 5 (18%) 
of 28 infected with S.  proliﬁ  cans and 1 (3%) of 31 infected 
with S. apiospermum. All deaths occurred in immunocom-
promised patients; 6 (43%) of 14 infected with S. proliﬁ  cans 
and 1 (5%) of 21 infected with S. apiospermum (odds ratio 
6.0, 95% conﬁ  dence interval 0.78–45.62, p = 0.05).
Drug-Susceptibility Testing
Drug-susceptibility testing was performed on 7 S. 
proliﬁ  cans isolates. MICs (mg/L) were >16 for ampho-
tericin B, >64 for ﬂ  uconazole, >8 for itraconazole, >64 
for 5-ﬂ  uorocytosine, and >16 for ketoconazole, 2–8 for 
voriconazole, and 1–4 for terbinaﬁ  ne.  Terbinaﬁ  ne  and 
itraconazole were synergistic for 3 of 6 isolates tested, 
and terbinaﬁ  ne and voriconazole were synergistic for 5 
of 7 isolates tested. Four S. apiospermum isolates tested 
Table 2. Characteristics of 8 patients with invasive disease and Scedospoeium prolificans infections, Australia, 1997–2003* 
Patient
no.
Primary 
disease
Transplant
type 
Neutropenia 
within 30 d  GVHD
Date of 
first
isolate
Days 
post
transplant Initial symptom 
Site of
isolates
Outcome
following 
diagnosis
1 ALL Allogeneic
HSCT
Yes Chronic 
extensive
Aug
2000
>400 Knee effusion  Blood,
synovium, 
cartilage,
prostate
Died d 21 
2 AML Allogeneic
HSCT
No Chronic
extensive
Apr
2001
>500 Pulmonary  
infiltrate 
Blood, sputum, 
BAL, lung 
Died d 5 
3 MM Allogeneic
HSCT
Yes No Nov
2000
28 Ethmoid sinus 
infiltrate 
Ethmoid sinus, 
vertebral disc, 
mycotic 
aneurysm 
Alive d 500 
4 NHL Allogeneic
HSCT
Yes No Dec
2000
10 Neutropenic  
sepsis
Blood Died before 
diagnosis
5 AML Allogeneic
HSCT
Yes No  Mar   
2003
10 Neutropenic  
sepsis
Blood, sputum, 
BAL, lung, skin 
Died d 1 
6 MM Allogeneic
HSCT
Yes Chronic 
extensive
Nov
2002
120 Pneumonia Sputum Died d 1 
7 MDS NA No NA Nov
2003
NA Maxillary sinus 
infiltrate 
Sputum,
maxillary sinus, 
pericardium,
myocardium, 
kidney, skin,  
lung
Died d 14 
8 AML NA Yes NA May 
2002
NA Catheter-related 
sepsis
Chest wall, 
Hickman
catheter
Alive d 500 
*GVHD, graft versus host disease; ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem cell transplantation; AML, acute myeloid leukemia; 
BAL, bronchoalveolar lavage; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndrome; NA, not applicable because 
patients did not undergo stem cell transplantation. RESEARCH
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had MICs of 0.5–1 mg/L for itraconazole and 0.5 mg/L 
for voriconazole.
Epidemiology of Scedosporium spp. 
and Aspergillus spp.
Throughout the study, S. apiospermum was isolated at 
a constant rate (Figure) of 3–6 isolates per year with no 
seasonal clustering. In contrast, S. proliﬁ  cans was ﬁ  rst de-
tected in December 1999, and thereafter ≈8 isolates were 
identiﬁ  ed annually. Detection of S. proliﬁ  cans continued 
in 2004 with 8 isolates but decreased to 6 in 2005 and 4 in 
2006. Two clusters of infection occurred in autumn 2001 
and 2003 during periods of hospital building that required 
deep excavation. Air, dust, and soil sampling did not de-
tect an environmental fungal source. Aspergillus spp. were 
detected during 1999–2005 (mean 191 persons per year, 
range 153–230). Detection rates for Scedosporium spp. 
and Aspergillus spp. for 2003–2005 were 0.1–0.23/1,000 
separations and 2–3/100,000 inpatient-patient days and 
2.4–3.0/1,000 separations and 53–75/100,000 inpatient-pa-
tient days, respectively.
Discussion
This study describes the epidemiology of Scedospo-
rium infection in a cohort of contemporaneous patients at a 
university hospital. The single-center approach, with cases 
identiﬁ  ed by laboratory detection, allows capture of the full 
spectrum of infection from colonization to invasive infec-
tion. Scedosporium spp. were detected in a broad range of 
patients and clinical settings. However, there were distinct 
differences in epidemiology, clinical manifestations, an-
tifungal susceptibility patterns, and outcomes between S. 
proliﬁ  cans and S. apiospermum.
Previous reviews have focused on invasive cases re-
ported (10,27,28), but this approach is limited by both se-
lection and publication bias (29) and does not describe the 
natural history of infection or the prevalence of these infec-
tions. Our series enables the annual incidence of cases, ra-
tio of colonized to infected patients, and natural history of 
colonization to be determined for each species. We showed 
that invasive infections accounted for only 6% of S. ap-
iospermum isolates and for 46% of S. proliﬁ  cans isolates, 
and that isolation of Aspergillus spp. was 20–30 times more 
frequent than that of Scedosporium spp.
S. apiospermum and S. proliﬁ  cans  are colonizers of 
abnormal airways caused by bronchiectasis, cystic ﬁ  brosis, 
chronic obstructive pulmonary disease, or lung transplanta-
tion (1,2,6,18,30,31). S. apiospermum was an airway colo-
nizer in <10% of patients with cystic ﬁ  brosis in France and 
Australia (1,2), and similar proportions of lung transplant 
recipients were colonized with 1 or both species at 1 cen-
ter in Australia (31). However, there are few reports that 
S. proliﬁ  cans colonized patients with lung disease (6,32). 
In the present study, S. proliﬁ  cans was identiﬁ  ed as an 
airway colonizer only after December 1999. The onset of 
invasive infections in HSCT and neutropenic patients oc-
curred in August 2000. S. proliﬁ  cans was ﬁ  rst detected at 
the M.D. Anderson Cancer Center in Houston, Texas, after 
2001 (19). Emergence of S. proliﬁ  cans may be related to 
an environmental source that was not identiﬁ  ed or selec-
tion pressure caused by changes in antifungal prophylaxis 
practices (33). This ﬁ  nding did not appear to be the expla-
nation in our patients because ﬂ  uconazole remains standard 
prophylaxis for neutropenia, and itraconazole was used in 
only 1 of 8 patients. Other possible explanations include 
use of more aggressive chemotherapy regimens in patients 
with acute leukemia and the advent of nonmyeloablative 
allografts, which change characteristics of patients selected 
for transplants. The reason for persistence of this organism 
over several years after its initial appearance is also unclear 
but has also been observed by others (19).
Figure. Epidemiologic curve of isolation of Scedosporium spp. isolation, Australia, June 1997–December 2003. S. proliﬁ  cans was ﬁ  rst 
identiﬁ  ed in December 1999 and had 2 peaks that coincided with construction work. S. apiospermum was isolated at a constant rate of 
1–2 times per 3-month period.Infection with Scedosporium spp., Australia
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In patients with respiratory tract disease, both Scedo-
sporium spp. were isolated in comparable numbers. How-
ever, the only invasive infection in this diverse group was 
disseminated S. apiospermum 5 years after lung transplan-
tion. The outcome of 19 patients who had undergone lung 
or heart lung transplantation and were colonized with this 
fungus was comparable to the 17 patients in the immuno-
competent group with airways disease caused by cystic 
ﬁ  brosis, bronchiectasis, or chronic obstructive pulmonary 
disease. As in other reports, other opportunistic pathogens, 
especially  Aspergillus spp. (present in one third), were 
commonly cultured simultaneously (1,18,30,31). In lung 
transplant recipients, Scedosporium spp. in BAL was as-
sociated with advanced bronchiolitis obliterans and airway 
stenosis (31), which emphasizes the difﬁ  culty of interpret-
ing the role of Scedosporium spp. in this group. Whether 
colonization follows airway damage, immunosuppression, 
or antifungal therapy to treat Aspergillus spp. coloniza-
tion or is itself an ongoing cause of airway damage such 
as bronchiolitis obliterans is unknown. In our study group, 
most patients with respiratory tract colonization had not re-
ceived antifungal therapy. Although antifungal treatment 
was used in ≈50% of patients with S. apiospermum airway 
colonization, there appeared to be no survival advantage in 
patients treated; our study was not a randomized compari-
son. With S. proliﬁ  cans respiratory tract colonization, too 
few patients were treated with antifungal drugs for valid 
conclusions to be made. There was no reduction in survival 
in 5 untreated patients with isolates of either S. apiosper-
mum or S. proliﬁ  cans. The role of Scedosporium spp. respi-
ratory tract colonization requires further evaluation.
Allogeneic HSCT and AML/MDS were the only settings 
in which S. proliﬁ  cans was more common than S. apiosper-
mum. There were no S. apiospermum infections in these 
patients, although in at 1 US cancer center, S. apiosper-
mum infections were more common (19). This may reﬂ  ect 
different geographic distributions of Scedosporium spp. In 
our study, S. proliﬁ  cans caused illness with high mortality 
rates in HSCT and leukemia patients. In HSCT recipients, 
S.  proliﬁ  cans infections occurred equally in those with 
neutropenia (early after transplant) and GVHD (later after 
transplant). Thus, host factors unique to AML and HSCT, 
such as neutropenia,  GVHD, associated macrophage dys-
function, and environmental exposure, may play a role in 
the propensity for invasive infection with S. proliﬁ  cans in 
this group.
As in previous reports (10,32), neutropenic patients 
had sepsis, positive blood cultures, and overwhelming in-
fection (often associated with disseminated rash). In non-
neutropenic patients, infection was more likely to be local-
ized initially in lungs, joints, or sinuses. The ability of S. 
proliﬁ  cans to grow in blood cultures in AML and HSCT 
patients is well recognized (10,34), and this diagnosis, or 
infection with Fusarium spp., should be considered when 
a mold is cultured from blood. In our study, S. proliﬁ  cans 
was the only species to grow in blood culture, although oth-
ers have reported S. apiospermum, albeit, less frequently 
(10,18,19). Although colonization with S. proliﬁ  cans with-
out progression to disease was observed in patients with 
respiratory disease and after lung transplantation, this was 
not observed in 3 patients with AML/MDS or HSCT. A 
nonsterile site swab or sputum culture yielding S. proliﬁ  -
cans was soon followed by a diagnosis of invasive infec-
tion, which indicated that in these patients a culture result, 
even from a nonsterile site, should be viewed seriously.
The clinical ﬁ  ndings of S. proliﬁ  cans in our patients 
suggest that this fungus is more invasive than S. apiosper-
mum, as has been found in mice (35). In addition to dissem-
inated infection in AML patients and HSCT recipients, S. 
proliﬁ  cans also caused locally invasive disease in patients 
who were not immunocompromised, such as those with 
posttrauma cellulitis, septic arthritis in a damaged joint, 
and sinus disease. One proposed mechanism for virulence 
of S. proliﬁ  cans is melanin in the cell wall (27).
Antifungal therapy is problematic with S. proliﬁ  cans 
with high MICs for amphotericin B, echinocandins, and 
azoles. This ﬁ  nding has stimulated interest in combinations 
of voriconazole and terbinaﬁ  ne (26), voriconazole and echi-
nocandin (36), or polyene and echinocandin (36). However, 
these infections are rare and experience is limited to case 
reports (8,9,36). In vitro treatment with interferon-γ and 
granulocyte-macrophage–colony-stimulating factor has 
improved neutrophil function against S. proliﬁ  cans hyphae 
(37). Surgery appears to be an important factor in survival 
in our cases, as well as other series (10). Although surgery 
and antifungal therapy were successful in 2 neutropenic 
patients with invasive S. proliﬁ  cans infections, these pa-
tients also had concomitant neutrophil recovery that could 
explain their survival.
Much needs to be learned about the epidemiology, 
transmission, pathogenesis, and environmental niche of 
Scedosporium spp., especially S. proliﬁ  cans. A source for 
emergence of S. proliﬁ  cans at our hospital was investigated, 
but none was identiﬁ  ed. Our inability to detect the source 
of emergent S. proliﬁ  cans was puzzling, although exposure 
and colonization may have occurred by the time the ﬁ  rst 
case was seen. Cultures may have been obtained too late 
to identify environmental contamination, although changes 
in immunosuppression in the population at risk may also 
have contributed. S. proliﬁ  cans appeared ﬁ  rst as a colonizer 
of abnormal airways 8 months before the ﬁ  rst invasive in-
fection in an HSCT recipient. Shifts in the epidemiology 
of colonizing organisms in this patient group during hos-
pital construction may be worthy of closer attention and 
surveillance. Molecular typing methods such as PCR (38) 
and inter-simple sequence repeat PCR ﬁ  ngerprinting (39) RESEARCH
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have distinguished genotypes from outbreaks and different 
geographic regions. Recently, S.  apiospermum complex 
has been shown to include several individual species in-
distinguishable morphologically (40). These methods will 
be used for further investigation of our isolates as part of a 
larger Australian surveillance study.
In conclusion, S. proliﬁ  cans and S. apiospermum are 
pathogenic fungi that demonstrate distinct clinical features 
dependent on the immune function of the host and the type 
of species isolated. They are usually found in patients with 
underlying disease, although occasionally after trauma. 
S.  proliﬁ  cans emerged as a major pathogen in allogeneic 
HSCT recipients and as a colonizer of patients with under-
lying lung disease. Madura foot is now rare and was not 
observed in this series. The high attributable mortality rate 
of invasive infection with both Scedosporium spp., limita-
tions of antifungal therapy, necessity for aggressive and de-
forming surgery to treat infections with S. proliﬁ  cans, and 
uncertainty over the role of airway colonization emphasize 
the need to better understand the epidemiology and patho-
genesis of this infection.
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